Abstract

Tyrosine Kinase Inhibitors in the Elderly: A Case Report and Literature Review on Toxicity Profiles

Tyrosine kinase inhibitors (TKIs) have emerged as the mainstay treatment for renal cell carcinoma (RCC). Despite growing popularity of TKIs, the treatment safety and tolerability in elderly patients are yet to be fully understood. As new assessment tools become available in identifying elderly patients with cancer at risk for severe treatment-related toxicities, much remains to be learned about how to integrate these tools into our management of elderly patients with cancer. We present a case of a 75- year-old man with RCC who was initially treated with pazopanib and subsequently treated with sunitinib. We review the safety and toxicity profiles of TKIs in treating elderly patients with RCC.


Author(s):

Aileen Deng, Andrew Chapman and Jianqing Lin



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+

Recommended Conferences

  • 23rd International Conference on Cancer Research & Pharmacology
    March 26-27, 2018, Edinburgh, Scotland
  • Cancer Genomics Conference: New Era for Cancer Prevention
    June 25-26, 2018 Dubai, UAE
  • 28th International Conference on Cancer Research and Anticancer Therapies
    September 17-18, 2018 San Diego, California, USA
  • Annual Congress on Cancer and Stem Cell Research
    October 19-20, 2018 Baltimore, Maryland, USA
Flyer image

Abstracted/Indexed in

  • Google Scholar
  • CiteFactor
  • WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research